FDA Greenlights Novel Colorectal Cancer Triplet Therapy Trial (Targeted Oncology)

Anbogen Therapeutics has received FDA clearance to launch a phase 1/2 trial of ABT-301, a selective HDAC1/2/3 inhibitor, in combination with tislelizumab and bevacizumab for metastatic colorectal cancer (mCRC). The study will focus on the 95% of mCRC cases that are pMMR/non-MSI-H “cold tumors,” which respond poorly to existing immunotherapies.